- 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. [Journal Article]
- EJEur J Nucl Med Mol Imaging 2018 Sep 19
- CONCLUSIONS: 225Ac-PSMA-617 RLT of chemotherapy-naïve patients with advanced metastatic prostate carcinoma led to a ≥ 90% decline in serum PSA in 82% of patients including 41% of patients with undetectable serum PSA who remained in remission 12 months after therapy. The remarkable therapeutic efficacy reported in this study could be achieved with reduced toxicity to salivary glands due to de-escalation of administered activities in subsequent treatment cycles. This necessitates further exploration for informing clinical practice and clinical trial design.
- Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. [Journal Article]
- UOUrol Oncol 2018 Sep 15
- CONCLUSIONS: We developed risk scores to predict CSS for patients treated with CN in the contemporary era. Patients with poor predicted survival may consider avoiding CN as initial management.
- [Cement augmentation for vertebral osteolytic metastatic lesions: an evaluation on postoperative CT]. [Journal Article]
- ZYZhonghua Yi Xue Za Zhi 2018 Sep 04; 98(33):2661-2665
- Objective: To evaluate the effectiveness of cement augmentation on the osteolytic lesion in patients with vertebral metastasis. Methods: A total of consecutive 132 patients with 268 vertebral metas...
Objective: To evaluate the effectiveness of cement augmentation on the osteolytic lesion in patients with vertebral metastasis. Methods: A total of consecutive 132 patients with 268 vertebral metastatic lesions treated with PVP from January 2008 to December 2016 in Zhongda Hospital were enrolled in this study. Retrospective analysis of preoperative, postoperative 3 days, 3 months, 6 months, 12 months and ≥ 18 months imaging data on CT, the local control and progression of the tumor were evaluated by MDA response criteria. The local control rates were compared between the groups with the different rate of cement filling by Chi2-test. Results: Vertebroplasty procedures were performed successfully in all 268 vertebrae under DSA guidance, and the mean volume of PMMA injected in each vertebra was 0.7-8.5(3.9±1.5)ml.The rate of local control at 3 months, 6 months, 12 months and ≥18 months after PVP was respectively 98.9%, 95.1%, 91.8%, and 85.2%, the difference was statistically significant(all P<0.05). The local control rate showed a statistically significant relationship to the groups with the rate of cement filling at 6 months, 12 months and ≥18 months after PVP, but there was no statistical difference at postoperative 3 months. The rate of local control was higher in 68 patients with lung or gastrointestinal cancer than in 17 patients with liver or kidney cancer at 3 months, 6 months and 12 months, the difference was statistically significant (P<0.05). Conclusion: Cement augmentation has a local anti-tumor effect on vertebral osteolytic metastatic lesion, and the anti-tumor effect will decrease as the follow-up time extended.
- Gamma Knife Radiosurgery for Metastatic Brain Tumors with Exophytic Hemorrhage. [Journal Article]
- JKJ Korean Neurosurg Soc 2018; 61(5):592-599
- CONCLUSIONS: Our experience shows that GKS performed in conjunction with our targeting technique safely and effectively treats hemorrhagic MBTs. The success of this technique may reflect the presence of scattered metastatic tumor cells in the hematoma that do not proliferate owing to the inadequate microenvironment of the hematoma. We suggest that GKS can be a useful treatment option for patients with hemorrhagic MBTs that are not amenable to surgery.
- Inflammatory myofibroblastic tumor of the pleura with adjacent chest wall invasion and metastasis to the kidney: a case report. [Journal Article]
- JMJ Med Case Rep 2018 Sep 09; 12(1):253
- CONCLUSIONS: Inflammatory myofibroblastic tumor is a rare neoplasm of intermediate malignant potential due to a tendency for local recurrence and it rarely develops distant metastases. Complete surgical resection is the primary treatment. However, unresectable and metastatic inflammatory myofibroblastic tumor can be treated with systemic therapy, including glucocorticoids, radiotherapy, and/or chemotherapy.
- The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma. [Journal Article]
- ARAnticancer Res 2018; 38(9):5339-5345
- CONCLUSIONS: Complete resection of metastatic sites for MRCC patients, combined with targeted therapy, could provide better overall survival rates than targeted therapy alone. Poor MSKCC risk is still correlated to a poor outcome in the current targeted therapy era.
- Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study. [Journal Article]
- INInvest New Drugs 2018 Sep 06
- Introduction Ketoconazole is CYP-17 inhibitor with demonstrated activity in men with castration-resistant prostate cancer (CRPC). Lenalidomide is an antiangiogenic and immunomodulatory agent with bro...
Introduction Ketoconazole is CYP-17 inhibitor with demonstrated activity in men with castration-resistant prostate cancer (CRPC). Lenalidomide is an antiangiogenic and immunomodulatory agent with broad antitumor activity. We hypothesized that the modulation of the cellular immune response to apoptosis caused by ketoconazole may be increased with the addition of lenalidomide. Methods This is an open-label, non-randomized, single-arm phase II study evaluating the efficacy and safety of the combination of ketoconazole and lenalidomide in patients with CRPC. Treatment schema included standard ketoconazole 400 mg orally three times daily plus hydrocortisone orally (20 mg in the morning and 10 mg at night) in combination with lenalidomide 25 mg orally daily for 21 days in a 28-day cycle and aspirin 75 mg daily. The primary endpoint of this study was response (either by ≥ 50% PSA decline or objective disease assessed by RECIST v1.0). Exploratory endpoints included changes in T cell, dendritic cell (DC) marker counts, and their correlation with PSA response to treatment. Results A total of 34 CRPC patients, median age 69 years, 76% ECOG 0 and 76% with metastases participated in the study. Patients received a median of 2 cycles (range 1-35); nine patients (26%) received >10 cycles of treatment. PSA responses were observed in 17 patients (50%) with 11 patients (32%) achieving a PSA decline of >90%. Among the 9 patients with measurable disease, 2 patients (22%) had PR and 2 other (22%) had SD as best response. Median time to failure (TTF) was 2.7 months (range 0.2-32.8); and 8 patients were treated for ≥ 15 months. Most common adverse events included fatigue (76%), skin reactions (62%), lymphopenia (44%) and anemia (44%). One possible treatment-related death was noted. For 16 patients with available serial correlative data, there was a significant increase in the dendritic cells subsets BDCA-1 (+146.7, -20.1 to +501.1%, p = 0.018) and BDCA-3 (39.8%, -100 to 282.6%, p = 0.001) after 8 weeks of treatment. No association between immune cell counts and PSA response at 8 weeks was observed. Conclusion The combination of ketoconazole and lenalidomide was well tolerated but did not meet the primary endpoint of response, despite durable responses were observed in a selected group of patients. Although ketoconazole has now been replaced with more active novel agents, the combination of novel CYP-17 inhibitors with agents capable of modulating the immune system warrants further prospective investigation. NCT00460031.
- Role of Stereotactic body radiation therapy in the management of oligometastatic renal cell carcinoma. [Journal Article]
- JUJ Urol 2018 Sep 01
- CONCLUSIONS: SBRT can be considered a safe approach and provides effective local control of oligometastatic RCC. However future prospective studies are necessary to evaluate its impact on survival and quality of life.
- Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. [Journal Article]
- BJBone Joint J 2018; 100-B(9):1241-1248
- CONCLUSIONS: Patients with bone or soft-tissue metastases from a RCC have a reasonable prognosis, making surgical resection a viable option even in patients in whom the metastases are advanced. Cite this article: Bone Joint J 2018;100-B:1241-8.
New Search Next
- Fine needle aspiration of giant cell tumor involving thyroid gland: A case report of an unprecedented entity. [Journal Article]
- DCDiagn Cytopathol 2018 Aug 26
- Fine-needle aspiration (FNA) is commonly used to evaluate both primary thyroid lesions (PTLs) and secondary thyroid neoplasms (STNs). Although STNs are uncommon, metastases from various primary sites...
Fine-needle aspiration (FNA) is commonly used to evaluate both primary thyroid lesions (PTLs) and secondary thyroid neoplasms (STNs). Although STNs are uncommon, metastases from various primary sites particularly the kidney, lung, and breast have been previously described. Giant cell tumor (GCT) is typically found in the metaphyseal-epiphyseal area of long bones that seldom involves thyroid. The typical cytological feature of GCT on FNA smears is highly cellular dual cell pattern consisting of mononuclear stromal cells and multinucleate osteoclast-like giant cells. By performing FNA of the left lobe of thyroid and clinico-radiological evaluation, we were able to diagnose a mass in a 40-year-old male patient as GCT based on cytological specimen. To the best of our knowledge, this is the first case that a GCT is identified in the thyroid gland by FNA initially.